BUFFALO, NY / ACCESSWIRE / August 6, 2014 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) will host a conference call and live webcast to discuss the results of the second quarter 2014, to be held Thursday, August 7, 2014 at 10:00 AM Eastern Time.
To participate in this event, dial 877-407-9205 domestically, or 201-689-8054 internationally, approximately 5 to 10 minutes before the beginning of the call. Alternatively, you can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=172979 as well as via the Cleveland BioLabs website (www.cbiolabs.com).
If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com/ClientPage.asp?ID=172979 or www.cbiolabs.com.
You may access the teleconference replay by dialing 877-660-6853 domestically or 201-612-7415 internationally, referencing conference ID #13586610. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on August 24, 2014.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are Entolimod, which is being developed as radiation countermeasure and a potential cancer treatment, and Curaxin CBL0137, our lead oncology product candidate. The company conducts business in the United States and in the Russian Federation through our three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.
SOURCE: Cleveland BioLabs, Inc.